170 related articles for article (PubMed ID: 18786288)
1. Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.
Le T; Faught W; Hopkins L; Fung-Kee-Fung M
J Obstet Gynaecol Can; 2008 Aug; 30(8):665-670. PubMed ID: 18786288
[TBL] [Abstract][Full Text] [Related]
2. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking.
Le T; Shahriari P; Hopkins L; Faught W; Fung Kee Fung M
Int J Gynecol Cancer; 2006; 16(3):986-90. PubMed ID: 16803473
[TBL] [Abstract][Full Text] [Related]
4. Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?
Le T; Faught W; Hopkins L; Fung-Kee-Fung M
J Obstet Gynaecol Can; 2009 Jan; 31(1):42-7. PubMed ID: 19208282
[TBL] [Abstract][Full Text] [Related]
5. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
6. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
[TBL] [Abstract][Full Text] [Related]
7. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
[TBL] [Abstract][Full Text] [Related]
8. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
Yoneoka Y; Ishikawa M; Uehara T; Shimizu H; Uno M; Murakami T; Kato T
J Gynecol Oncol; 2019 Sep; 30(5):e81. PubMed ID: 31328461
[TBL] [Abstract][Full Text] [Related]
11. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
13. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
15. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
[TBL] [Abstract][Full Text] [Related]
16. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
Pelissier A; Bonneau C; Chéreau E; DE LA Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Anticancer Res; 2016 Apr; 36(4):1865-71. PubMed ID: 27069172
[TBL] [Abstract][Full Text] [Related]
18. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
19. Value of Diaphragmatic Surgery During Interval Debulking Surgery.
Pelissier A; Franke O; Darai E; Houvenaeghel G; Chereau E; Rouzier R
Anticancer Res; 2018 Jan; 38(1):411-416. PubMed ID: 29277802
[TBL] [Abstract][Full Text] [Related]
20. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer.
Le T; Faught W; Hopkins L; Fung Kee Fung M
Int J Gynecol Cancer; 2005; 15(5):770-5. PubMed ID: 16174222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]